<DOC>
	<DOCNO>NCT02814461</DOCNO>
	<brief_summary>To determine maximal tolerate dose ( MTD ) axitinib combination RT advance HCC .</brief_summary>
	<brief_title>The Safety Maximum Tolerated Dose Axitinib Combination With Radiotherapy HCC</brief_title>
	<detailed_description>The goal study conduct phase I clinical trial evaluate safety MTD axitinib combination RT advance HCC . There rationales conduct clinical trial . Firstly , evidence benefit combination variety anti-angiogenic agent RT pre-clinical level . Numerous pre-clinical model document improved outcome combination RT ( e.g . bevacizumab ... etc ) . Potential increase oxygenation tumor anti-angiogenesis also expect improve therapeutic ratio radiation therapy hypervascular caner like HCC . Secondly , spatial cooperation may exist local treatment ( e.g . RT ) systemic therapy ( e.g . axitinib ) . From experience sorafenib , majority patient eventually progress within liver die liver failure , provide rationale use local therapy like RT . On hand , experience RT , common site first recurrence liver outside irradiated volume , provide rationale study combine regional systemic therapy RT . Thirdly , clinical experience RT anti-angiogenic agent still exist encouraging result . For example , one retrospective review Taiwan advance HCC treat RT sunitinib ( TKI similar mechanism sorafenib ) report objective response rate 74 % median survival 16 month , conclude hypofractionated RT sunitinib deliver safely HCC patient , compatible result several phase I II study use sorafenib plus . Fourthly , safety MTD axitinib combine RT need establish launch phase II study</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Age 2085 year , ECOG performance 02 . Advanced hepatocellular carcinoma ( HCC ) , histologically clinically diagnose . ( Multiple tumor , portal vein thrombosis , nodal metastasis distant metastasis allow . ) Unsuitable resection , liver transplantation , radiofrequency ablation ( RFA ) transarterial chemoembolization ( TACE ) , recurrent / refractory prior localregional treatment . ≥ One measurable tumor . ChildPugh score A B . Patients fulfill follow criterion : 1 . Serum total bilirubin ≤ 3 mg/dL 2 . Serum alanine transaminase ( ALT ) ≤ 5 time ULN 3 . INR ≤ 2.20 4 . Platelet count ≥ 50,000 /mm3 5 . WBC count ≥ 3,000 /mm3 ANC ≥ 1,500 /mm3 6 . Serum creatinine ≤ 2.0 mg/dL Normal thyroid function confirm . Absence grant sorafenib . Sorafenib failure intolerability ( ever use ) . Considered high risk bleeding ( e.g . active peptic ulcer , unstable esophageal/gastric varix , history aneurysm , requirement anticoagulant therapy ) . Preexisting uncontrolled hypertension ( systolic &gt; 140 mmHg , diastolic &gt; 90 mmHg ) proteinuria ≧500 mg/24 hour . Prior history coronary artery disease . The patient participate clinical trial . Pregnant woman . Patients rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption . Patients nonhealing wound . Requiring use potent CYP3A4/5 inhibitor inducer ( see Appendix ) . Other severe acute chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation judgment investigator would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>